The research, led by Linlin Cao and colleagues, drew on plasma samples collected from 18,476 participants between one and 96 years of age at six clinical centers across China. Rather than focusing on a narrow age band or a single disease population, the team deliberately captured the full arc of human development, from childhood through extreme old age. Each participant’s blood plasma was subjected to metabolomic profiling, a technique that measures the small molecules, including lipids, amino acids, and other intermediates of metabolism, that circulate in the bloodstream and reflect the combined output of genes, environment, diet, and organ function. Because metabolites sit at the functional endpoint of biology, they are often more sensitive to the real-time physiological state of the body than genetic sequences, which remain fixed throughout life.

From this vast dataset, the researchers identified 56 metabolites whose abundance shifted in patterns reliably tied to age. These were not random fluctuations. The molecules formed coherent signatures of the biochemical remodeling that accompanies aging, capturing changes in energy metabolism, inflammatory pathways, and lipid handling that accumulate as tissues and organs gradually lose resilience. The team then used ensemble learning, a machine learning strategy that combines multiple predictive models to improve accuracy and robustness, to distill these signatures into quantitative aging clocks. The approach mirrors the logic of epigenetic clocks, which estimate biological age from DNA methylation patterns, but operates instead on the metabolic layer, which is cheaper to measure in clinical settings and more directly tied to current health status.

The central product of this modeling effort is a metric the researchers call metabolomic age acceleration, abbreviated mAA. The concept is elegantly simple: the models estimate a person’s metabolic age from their plasma profile, and that estimate is compared with the person’s actual chronological age. If the metabolic age exceeds the chronological age, the individual is said to exhibit age acceleration, a signal that their body is aging faster at the biochemical level than the calendar would suggest. Conversely, a metabolic age below chronological age points to slower biological aging. What elevates the finding from an interesting curiosity to a clinically meaningful measure is its predictive power. In the cohort, higher mAA correlated with an elevated risk of developing metabolic-associated fatty liver disease, hypertension, and type 2 diabetes, as well as with a greater likelihood of death from any cause as participants were followed over time.

These associations matter because they suggest that metabolic aging clocks capture something real about the trajectory of health rather than merely restating how old someone is. Chronological age is already one of the strongest risk factors for virtually every chronic disease, yet two people of the same age can occupy dramatically different positions on the path to illness. A biomarker that quantifies that divergence, using a single blood draw and a standardized computational pipeline, could allow physicians to identify high-risk individuals years before symptoms appear, when lifestyle interventions and preventive treatment are most effective. The authors emphasize that the framework is designed to be scalable, meaning it could in principle be deployed across large health systems and population screening programs without the prohibitive costs associated with whole-genome sequencing or repeated imaging.

The study did not stop at the general population. The team also examined a separate disease cohort, and in doing so uncovered a second metabolic metric they term age deviation. Unlike mAA, which is calibrated on healthy aging trajectories, age deviation quantifies how far an individual’s metabolic profile strays from the expected pattern for their age. In patients, higher age deviation was associated with more severe and more systemic disease, suggesting that the measure registers the degree to which illness disrupts the body’s normal metabolic architecture. This distinction is conceptually important. Age acceleration may reflect the slow drift of biological aging, while age deviation appears to capture acute or pathological departures from that drift, offering a complementary lens on the relationship between aging and disease.

One of the study’s most valuable contributions is the sheer depth of the underlying data. Metabolomic studies of aging have often been limited to small cohorts, restricted age ranges, or single measurement platforms, making it difficult to distinguish genuine aging signals from noise, cohort effects, or confounding by disease. By profiling nearly 18,500 individuals across the full lifespan, the Chinese team produced a reference map of how hundreds of circulating metabolites change from infancy to the tenth decade of life. This treasure trove, as the release describes it, will serve as a resource for other researchers seeking to understand which biochemical pathways drive aging, which are merely passengers, and how environmental factors such as diet, region, and socioeconomic conditions modify the aging process in different populations.

The clinical implications extend in several directions. First, the mAA metric could be incorporated into routine health checkups as a single interpretable number, analogous to how blood pressure or cholesterol are used today, flagging individuals whose metabolic systems are aging prematurely. Second, the age deviation measure could serve as a severity marker in hospitalized patients or those with chronic conditions, helping clinicians gauge how systemically a disease has disturbed normal physiology. Third, the clocks could accelerate clinical trials of interventions intended to slow aging, from exercise and dietary programs to future geroprotective drugs, by providing a quantitative endpoint that responds over months or years rather than waiting decades for hard outcomes such as mortality. The researchers have made their age prediction framework publicly accessible through a web interface hosted by their laboratory, lowering the barrier for other scientists to apply and validate the tools.

As with any biomarker study, important questions remain before metabolic aging clocks enter everyday practice. The cohort was drawn exclusively from Chinese clinical centers, and metabolite levels can vary with ancestry, diet, and local environmental exposures, so validation in other populations will be essential. The associations between mAA and disease risk, while robust within the study, will need to be tested prospectively to determine whether the metric genuinely adds predictive value beyond established clinical risk scores. It is also not yet clear whether interventions that lower metabolic age acceleration translate into longer, healthier lives, a question that only longitudinal trials can answer. Nevertheless, the scale and rigor of this study mark a significant advance in the effort to quantify aging as a measurable, modifiable process, and they support the authors’ conclusion that plasma metabolomics offers a practical foundation for studying disease prevention, early detection, and healthy aging across the life course.

The work arrives at a moment of surging interest in geroscience, the field devoted to understanding and intervening in the biology of aging. Epigenetic clocks have already demonstrated that biological age can be estimated from molecular data and that it varies meaningfully between individuals, but their reliance on DNA methylation arrays has limited clinical uptake. Metabolic clocks, built from standard blood chemistry and machine learning, could prove more adaptable to existing laboratory infrastructure. If subsequent studies confirm the predictive power reported here, a routine blood test may one day tell patients not just how old they are, but how fast they are aging, and whether the trajectory they are on leads toward chronic disease or toward a longer healthspan. For now, the study stands as a demonstration that the molecular clocks of human aging can be read from a vial of blood, and that what they reveal may be among the most informative numbers in preventive medicine.

Subject of Research: Metabolomic aging clocks that predict chronic disease and mortality risk across the human lifespan

Article Title: Large clinical study in China uncovers “clocks” of human aging that may predict chronic disease and mortality

Article References: Large clinical study in China uncovers “clocks” of human aging that may predict chronic disease and mortality. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: aging clocks, metabolomics, biomarkers, chronic disease, mortality prediction, fatty liver disease, hypertension, diabetes, machine learning, Science Translational Medicine, healthy aging, plasma metabolites

The discovery did not begin with a hypothesis about any particular bacterium. Instead, the researchers built AURORA, a generative artificial intelligence framework that integrates multiple data modalities, including metagenomic sequences, plasma metabolomics, gene expression and physiological measurements, into a unified model of human aging. Within this framework, the team constructed multi-modality aging clocks, statistical models that estimate a person’s biological age from molecular and phenotypic features, and then used the model to perform in silico screening: systematically simulating thousands of potential interventions to identify which changes would most effectively reduce the gap between predicted biological age and chronological age.

That computational screen produced an unexpected front-runner. When the abundance of Neisseria flavescens was virtually increased in the model, the predicted age gap shifted in a favorable direction, and the simulated perturbation also produced beneficial changes in physiological signatures, promoted the abundance of known health-associated gut taxa and enhanced the biosynthesis of metabolites with documented benefits. In a natural human aging cohort, individuals classified as slow agers, whose biological clocks ran younger than their chronological years, carried significantly more of this oral species than fast agers. The association was replicated in longitudinal data tracking one-year changes in bacterial abundance against changes in the aging measure.

To move beyond correlation, the team isolated two live strains of N. flavescens, designated a11 and e5, from human donors and sequenced their genomes, which have been deposited under the accessions GWHHOEZ01000000 and GWHHOEA01000000. Laboratory analysis confirmed that both strains actively produce vitamins and other beneficial metabolites predicted by the computational framework. Targeted mass spectrometry of bacterial culture supernatants verified the metabolic output, providing a mechanistic bridge between the human association data and the biological activity of the organism itself.

The first functional test took place in Caenorhabditis elegans, the transparent roundworm that has long served as a workhorse of aging research. When worms were fed live N. flavescens instead of their standard laboratory diet of Escherichia coli OP50, their lifespans lengthened and their healthspans, the portion of life spent in good condition, improved. Supplementation also attenuated the age-related decline in mobility during early adulthood and altered body size, with independent replication experiments confirming the lifespan extension for both strains. Heat-killed bacteria likewise preserved worm mobility, hinting that structural components of the microbe, rather than only its living metabolic activity, may contribute to the effect.

In aged mice, the researchers turned to heat-killed N. flavescens, a form of supplementation that avoids the safety considerations of administering a live organism. After ten weeks of treatment, the animals’ serum metabolome, liver transcriptome and gut microbiome all shifted measurably toward younger profiles. Principal-component analyses showed that the metabolic and transcriptional states of treated twenty-month-old mice moved closer to those of young two-month-old controls, and regression analysis demonstrated that treatment-associated fold changes across metabolites, microbial species, microbial pathways and liver transcripts tended to oppose the changes normally driven by aging itself. The effect was partial rather than a wholesale reversal, but the consistent directional rescue across three distinct molecular layers is striking.

The study also addressed how an oral bacterium could plausibly influence systemic aging. Paired analyses of oral and gut microbiome data, including paired samples from the Human Microbiome Project, revealed links between N. flavescens abundance and the composition of the gut ecosystem, including associations with Akkermansia muciniphila, a gut bacterium widely studied for its beneficial effects on metabolic health and barrier function. Predicted downstream effects included changes in immune signaling pathways in peripheral blood mononuclear cells, suggesting a route by which oral microbial signals propagate through host metabolism and immunity rather than acting locally in the mouth alone.

Technically, the work represents a notable advance in how candidate interventions are identified. Traditional microbiome-aging studies typically search for correlations between individual taxa and chronological age or survival, an approach that the authors note would not have singled out N. flavescens as a top hit in their own data. By instead simulating perturbations within a generative model trained on multi-omics data, AURORA can prioritize organisms whose expansion is predicted to shift the entire aging state favorably, a logic closer to a causal intervention than a population association. The framework and all analysis code are freely available, and the underlying sequencing datasets have been deposited in public repositories under BioProject PRJCA057750 and associated accessions.

Important caveats remain. The human evidence is associative, the mouse experiments used heat-killed preparations whose active components have not yet been identified, and no human intervention trial has been conducted. A patent covering N. flavescens and its applications is pending, filed by two of the authors, which signals commercial interest but also that translational development is still at an early stage. Even so, the convergence of computational prediction, human cohort data, worm lifespan experiments and mouse molecular rescue makes a compelling case that the mouth, a microbiome site routinely dismissed as merely a gateway to dental disease, deserves far more attention in geroscience. If the findings hold up in further studies, the next geroprotective intervention might not come from a laboratory-synthesized molecule but from a common commensal already living between our teeth.

Subject of Research: Identification of the oral commensal Neisseria flavescens as a geroprotective microbe linked to decelerated human aging

Article Title: Multi-modality profiling identifies Neisseria flavescens as a central geroprotective oral commensal in humans

Article References: Chen, J., Ren, Y., Zhou, Y., Wang, Z., Li, J., Guo, X., Xu, H., Wang, Y., Tang, H., & Han, J.-D. J. (2026). Multi-modality profiling identifies Neisseria flavescens as a central geroprotective oral commensal in humans. Nature Aging. https://doi.org/10.1038/s43587-026-01220-0

Image Credits: AI Generated

DOI: 10.1038/s43587-026-01220-0

Keywords: aging, oral microbiome, Neisseria flavescens, AURORA, geroprotection, aging clocks, multi-omics, Caenorhabditis elegans, gut microbiome, probiotics, longevity, metabolomics

The study, conducted by Dongdong Zhang of the Wuwei Center for Disease Control and Prevention in China, constructed not one aging clock but 49 of them: 47 transcriptomic clocks trained on individual human tissue types and two trained on cell-line categories. The underlying data came from the Genotype-Tissue Expression project, known as GTEx version 8, which catalogs gene expression across the human body and contributed samples from 948 unique donors to the retained clock categories. Rather than blending these tissues into a single model, Zhang trained a separate elastic-net regression for each category, predicting chronological age from gene expression, and evaluated every clock using donor-grouped cross-validation, a design that prevents the same individual’s samples from leaking between training and test sets.

The performance of these clocks varied considerably, and that variation is itself informative. The median Pearson correlation between predicted and chronological age across all 49 clocks was 0.543, a respectable but far from perfect figure that reflects the noisy relationship between transcript levels and elapsed time. At the top end, the clock trained on the aorta achieved a correlation of 0.855, making the body’s largest artery the most transcriptionally age-accurate tissue in the dataset. This spread suggests that some tissues carry far stronger and more consistent age-related transcriptional signals than others, a finding consistent with growing evidence from plasma proteome studies that organs age at measurably different rates and that organ-specific aging signatures track health and disease.

Across all clocks, the analysis identified 10,253 unique genes that the elastic-net procedure had selected as age predictors. Strikingly, 69.2 percent of these clock genes appeared in only one tissue, a degree of overlap so low that it might seem to prove that each organ ages through its own dedicated molecular program. But the study did something that many clock papers skip: it ran a null simulation. When the same elastic-net selection procedure was applied to shuffled data, it produced similarly sparse, minimally overlapping gene sets. In other words, the apparent tissue-specificity of clock genes is largely the expected statistical consequence of applying a sparse regularization method to high-dimensional data, not necessarily evidence of profound biological divergence between tissues. It is a methodological caution that ripples well beyond this study, touching any field that interprets which features a machine-learning model selects rather than how well it predicts.

The second half of the study is where the work becomes genuinely provocative for the drug discovery community. Zhang projected 3,926 compound-name entries from the Library of Integrated Network-Based Cellular Signatures, or LINCS L1000, onto each of the 49 tissue clocks. The logic is a familiar one in connectivity-map style analyses: if a drug’s known gene-expression signature pushes a tissue’s aging clock backward, that drug might be a candidate anti-aging compound for that tissue; if it pushes the clock forward, the drug might be accelerating that tissue’s transcriptional aging. The result is a vast drug-by-category matrix of age-reversal scores covering 192,374 drug-tissue pairs, a resource the author describes as tissue-aware and hypothesis-generating.

What emerged from that matrix is a picture of profound drug heterogeneity. At a permissive threshold, with absolute scores above 1.0, 94.2 percent of drugs showed mixed score directions, meaning they appeared to reverse transcriptional aging in some tissue categories while appearing to accelerate it in others. This near-universal mixed behavior, however, was descriptive and did not itself exceed what shuffled data produced, so the study is careful not to claim it as a biological discovery. Under a far more stringent exploratory criterion, requiring absolute scores above 2.0 in at least three categories in each direction, 2.8 percent of compound entries showed pronounced bidirectional divergence, compared with roughly 0.1 percent under the shuffled null. That roughly thirtyfold enrichment over chance suggests that a small subset of compounds genuinely produces structured, tissue-dependent transcriptional signals that cannot be explained by noise alone.

Robustness checks form the backbone of the paper’s credibility. When the compound rankings were recomputed using only the 34 clocks whose correlations reached at least 0.5, the rankings remained highly stable, with a Spearman correlation of 0.897 against the full analysis. A completely independent enrichment method based on Jaccard overlap produced nearly identical compound orderings, with a median per-category Spearman correlation of 0.961, demonstrating that the findings were not artifacts of one particular scoring approach. Four additional statistical robustness tests confirmed model stability. Yet the study is equally forthright about the limits of its own conclusions: after Benjamini-Hochberg false discovery rate correction across all 192,374 drug-category pairs, only 0.79 percent of pairs reached significance at FDR below 0.05. Individual drug-tissue calls, the paper emphasizes, demand caution and experimental validation before anyone treats them as actionable.

One result will raise eyebrows among longevity enthusiasts. Rapamycin, the mTOR inhibitor that robustly extends lifespan in mice and anchors much of the geroscience agenda, showed net pro-aging transcriptional signatures in this system. The author explicitly and repeatedly stresses that transcriptome-based scores and organismal lifespan are distinct endpoints. A drug can shift the expression levels of age-associated genes in adult human tissue samples without shortening or lengthening life, and rapamycin’s well-documented lifespan effects in animal models involve mechanisms, including immune modulation and long-term metabolic reprogramming, that a static transcriptional score cannot capture. The finding is best read as a demonstration of the method’s limits and a warning against equating clock reversal with rejuvenation, rather than as evidence against rapamycin itself.

The study also ventured into causal territory using the Cancer Dependency Map, or DepMap, repeating CRISPR-based gene dependency analyses after standardizing on GTEx-derived data across 13 matched tissue categories. The author acknowledges that individual gene-level results from this component were limited, positioning it as a secondary exploration rather than a headline finding. All datasets used in the study, including GTEx v8, LINCS L1000, and DepMap, are publicly available without application, and the complete analysis code has been released on GitHub, making the entire pipeline reproducible and extensible by other groups.

The broader significance of this work lies less in any single drug-tissue prediction than in the framework it establishes. It shows that tissue-resolved aging clocks are feasible at scale, that their gene selections must be interpreted through the lens of statistical regularization rather than taken as direct biology, and that drug effects on aging signatures are structured but overwhelmingly tissue-dependent. For a field increasingly animated by the prospect of repurposing existing drugs against aging, the message is double-edged: computational screens can generate rich, testable hypotheses about which compounds might help which organs, but the same screen that flags a candidate in one tissue may flag the same compound as harmful in another. Bridging that gap between transcriptional pattern and therapeutic reality will require exactly what this study cannot provide: controlled experiments in living systems, tissue by tissue, drug by drug.

Subject of Research: Tissue-specific transcriptomic aging clocks and their use to profile tissue-dependent drug effects on aging across 49 human tissue and cell-line categories

Article Title: Tissue-specific aging clocks map structured aging-modulatory drug-score patterns across 49 human tissue and cell-line categories

Article References: Zhang, D. (2026). Tissue-specific aging clocks map structured aging-modulatory drug-score patterns across 49 human tissue and cell-line categories. Biogerontology, 27(5), Article 163. https://doi.org/10.1007/s10522-026-10512-2

Image Credits: AI Generated

DOI: 10.1007/s10522-026-10512-2

Keywords: aging clock, tissue-specific aging, GTEx, LINCS L1000, drug repurposing, transcriptomics, elastic net, biological age prediction, rapamycin, DepMap, Biogerontology, drug heterogeneity

The journey begins in New York, where Founder and Chief Executive Officer Dr. Alex Zhavoronkov will attend the Morgan Stanley 24th Annual Global Healthcare Conference from September 14 to 16. On September 15 at 14:35, Zhavoronkov is scheduled to participate in an in-person fireside chat, engaging global investors and industry leaders on the company’s latest advances in generative AI-driven drug discovery, aging clocks and anti-aging interventions. The Morgan Stanley conference is widely regarded as one of the largest and most influential healthcare investment gatherings in the world, convening thousands of leaders each year, from multinational pharmaceutical companies and biotech innovators to medical device makers, digital health pioneers, hedge funds, long-only investors, consulting firms and regulatory bodies. Its mix of keynote addresses, fireside chats, one-on-one investor meetings and forward-looking roundtables makes it a core venue where international capital identifies healthcare opportunities and where large pharmaceutical companies scout innovative technologies and potential acquisition targets.

For Zhavoronkov, the New York appearance is an opportunity to present Insilico’s progress to the capital markets at a moment of unusual momentum. The company has been steadily expanding its narrative beyond a single headline asset, highlighting an end-to-end autonomous laboratory roadmap that pairs its generative chemistry platforms with laboratory automation designed to compress the timelines of target identification, molecular design and preclinical validation. The aging research dimension of the company’s work, including its well-known deep learning aging clocks that estimate biological age from multimodal data, has long differentiated Insilico from AI drug discovery peers, and executives are expected to weave that longevity science perspective into their dialogue with investors who increasingly view aging biology as a fertile ground for new therapeutics.

From New York the focus shifts to the Middle East. Dr. Alex Aliper, Co-Founder and President of Insilico Medicine, has been invited to the Riyadh Global Medical Biotechnology Summit, known as RGMBS 2026, running September 14 to 16 in the Saudi capital. On September 16, from 09:00 to 12:00 at the Sofitel Riyadh Hotel and Convention Center, Aliper will lead the Insilico team in hosting a hands-on workshop titled Model Context Protocol-Empowered Protein Design: Combining AI Foundation Models and Physics-Based Molecular Modelling. The session is designed to be intensely practical. Participants will gain first-hand experience using the Model Context Protocol, or MCP, to connect AI foundation models, molecular simulation engines and chemical databases. The curriculum covers the complete workflow from protein and ligand structure preparation through physics-based validation, teaching attendees how to score and prioritize drug candidates with AlphaFold, RDKit and OpenMM, how to interpret binding modes, kinetics and free-energy calculation results, and how to run a directed MCP workflow inside Insilico’s Chemistry42 sandbox environment.

The choice of technical material is significant. The Model Context Protocol has emerged as an open standard for connecting large AI models with external tools and data sources, and Insilico’s workshop represents one of the most concrete demonstrations of how that architecture can be applied to protein engineering and small-molecule discovery. By linking generative foundation models to physics-based simulation, the workflow aims to marry the speed and creativity of deep learning with the rigor of molecular mechanics, free-energy perturbation and kinetics analysis that medicinal chemists have long demanded. Aliper, who has spent much of his career at the intersection of AI-driven drug discovery, frontier biomedical science and cross-disciplinary tool integration, will also use the summit to showcase Insilico’s role in building the Chemistry42 generative chemistry platform and the company’s broader autonomous laboratory ecosystem, positioning the workshop as a window into how modern AI-native biopharma companies orchestrate computational and experimental workflows.

RGMBS 2026 itself carries strategic weight. Co-initiated by the Saudi Ministry of Health, the Royal Commission for Riyadh City and leading biomedical authorities, the summit is one of the largest international biotechnology and medical innovation gatherings in the Middle East. It convenes scientists, research and development leaders, clinical experts, regulators and strategic investors spanning biopharmaceuticals, gene and cell therapy, medical devices, digital health and fundamental life sciences. Organizers have centered the program on frontier biotechnology, precision medicine, AI-driven drug discovery, translational medicine, health-tech investment and biomanufacturing, using keynote addresses, themed workshops, closed-door sessions, industry matchmaking and project roadshows to drive cross-regional collaboration. For global biopharma companies, the event is increasingly viewed as a gateway to the Middle East market and to Saudi Vision 2030, the kingdom’s national strategy that places biomedical capability among its economic diversification priorities.

The third stop brings Insilico to Shanghai, where Co-CEO and Chief Scientific Officer Dr. Feng Ren will attend Bio-Shanghai Week 2026, an event anchored by Zhangjiang Drug Valley, a national-level biopharmaceutical industry hub. On September 17 at 15:00, during the opening ceremony’s AI-Driven Innovation session, Ren will engage in an in-depth dialogue with Professor Michael Levitt, the 2013 Nobel Laureate in Chemistry and Stanford University structural biology professor, on the theme of AI-driven global innovation in therapeutic target discovery and treatment technologies. The conversation is expected to traverse three dimensions: foundational science breakthroughs, industrial translation pathways and global strategic coordination, examining how artificial intelligence is systematically reshaping the full chain from target discovery through molecular design to clinical development. Ren, regarded as one of the leading scientists driving AI-enabled drug research and clinical translation in China, will share Insilico’s generative AI platform, its pipeline progress and the company’s global footprint, creating what organizers describe as a high-level exchange between a leading Chinese AI-driven pharmaceutical company and a top global scientist.

Bio-Shanghai Week ranks among the largest and most internationally influential biopharmaceutical industry events in Shanghai, drawing leading scientists, clinical experts, multinational pharmaceutical and biotech companies, innovative drug and device developers, investors, regulators and industry service platforms. Its agenda spans AI-driven innovation, gene and cell therapy, antibodies and antibody-drug conjugates, rare diseases, neuroscience, global market access, clinical translation and the broader industry ecosystem. The event serves as a vital window into the frontier of China’s biopharmaceutical industry and the wider Yangtze River Delta innovation ecosystem, a region that has become one of the world’s densest concentrations of drug discovery talent and capital.

The final leg of the tour takes Zhavoronkov to Boston on September 18 for the Harvard IvyTech Discussion, co-initiated by Harvard University and other Ivy League academic institutions. From 10:50 to 12:00, he will deliver a keynote address in a forum titled A Geo-Economic Shift: China’s Rise as an Innovation Powerhouse in Biotech. Sharing the stage with leading scientists, industry strategists and policy researchers from North America’s top institutions, Zhavoronkov will discuss the leapfrog transformation of China’s biopharmaceutical industry from generic manufacturing to first-in-class innovation, and the corresponding evolution of the global biopharma value chain and capital landscape. He is also expected to present Insilico’s strategic blueprint as what the company calls a bridge enterprise connecting Eastern and Western innovation ecosystems, spanning Chinese foundational research, the company’s AI platform technology, its global research and development pipeline, and its international capital and industry partnerships. The IvyTech platform, which focuses on frontier technology, industrial transformation and geo-economic topics, brings together scientists, technology executives, entrepreneurs, policymakers and institutional investors for dialogue across biomedical innovation, artificial intelligence, advanced manufacturing, the energy transition and cross-border innovation ecosystems.

The speaking tour arrives at a pivotal financial and scientific moment for Insilico Medicine. The company recently reported total revenue of approximately 106 million US dollars in the first half of 2026, a 287 percent year-over-year increase, and achieved its first profitable half-year since listing, with adjusted net profit exceeding 51 million dollars. The milestone was driven by a series of out-licensing, co-development and research collaborations with global partners including Eli Lilly, Servier, Takeda, SK Biopharmaceuticals, Qilu Pharmaceutical, Hygtia Therapeutics, CMS and Tenacia. As of the latest practicable date, the total contract value of transactions announced by the company in 2026 reached approximately 7.3 billion dollars, pushing the cumulative contract value of its major collaborations since 2021 to roughly 11 billion dollars. On the research front, Insilico nominated nine development candidates within the first nine months of 2026 as of late August, a company record for annual pipeline productivity, and achieved eight clinical milestones across its proprietary and co-developed programs. Leading that progress is rentosertib, also known as ISM001-055, the world’s first drug candidate discovered and developed using generative AI, which has advanced into a Phase III trial evaluating treatment for idiopathic pulmonary fibrosis, a progressive and often fatal scarring lung disease with few therapeutic options. Listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025 under the stock code 03696.HK, Insilico continues to apply its Pharma.AI platform to fibrosis, oncology, immunology, pain, obesity and metabolic disorders, while extending the technology into advanced materials, agriculture, nutritional products and veterinary medicine. The four-city executive tour, spanning capital markets in New York, biotechnology diplomacy in Riyadh, scientific dialogue in Shanghai and academic strategy in Boston, functions as a compressed portrait of the company’s thesis: that generative AI, rigorous physics-based validation and global collaboration can deliver better drugs faster, and that the companies able to bridge the world’s major innovation hubs will define the next decade of biopharmaceutical progress.

Subject of Research: Insilico Medicine executive participation in four global healthcare and AI summits showcasing generative AI drug discovery

Article Title: Across four global innovation hubs: Insilico Medicine executive team to speak at premier healthcare and AI Summits

Article References: Across four global innovation hubs: Insilico Medicine executive team to speak at premier healthcare and AI Summits. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Insilico Medicine, generative AI, drug discovery, rentosertib, AlphaFold, Model Context Protocol, aging clocks, biotechnology, idiopathic pulmonary fibrosis, AI summits, autonomous laboratory, biopharmaceutical innovation

At the heart of this debate lies the evolutionary principle of natural selection, whose strength diminishes after an organism reaches reproductive maturity. This decline in selective pressure implies that aging need not be programmed actively; rather, it may be a secondary consequence of the gradual breakdown of cellular repair mechanisms. Damage accrues in the form of DNA mutations, protein misfolding, epigenetic alterations, and mitochondrial dysfunction, all contributing to systemic entropy and functional decline. This perspective sharply contrasts with programmed aging theories, which posit that aging is a genetically encoded process aimed at an evolutionary purpose, such as population control or resource allocation.

Recent investigations utilizing cross-species comparisons have provided compelling evidence for the stochastic damage model. Longevity in mammals correlates strongly with enhanced capacities for DNA repair, suggesting that an organism’s ability to maintain genomic integrity is a pivotal determinant of lifespan. Species with exceptional longevity, such as certain bats and whales, exhibit robust DNA repair pathways and superior proteostasis networks, which effectively mitigate the accumulation of molecular damage over time. These findings indicate that lifespan extension strategies might be more successful if they focus on augmenting cellular maintenance rather than targeting hypothetical aging programs.

The precision of modern aging clocks stems from the integration of multiple molecular markers, including DNA methylation patterns, transcriptomic changes, and proteomic alterations. These clocks provide a snapshot of biological age by quantifying deviations from youthful molecular states. While the accuracy of these clocks is remarkable, their predictive power does not necessarily imply underlying biological programming. Instead, they appear to measure the composite burden of stochastic damage that accumulates as maintenance mechanisms become less efficient with age. Thus, aging clocks serve as powerful tools for quantifying biological age and healthspan but should not be misconstrued as proof of a programmed aging process.

In addressing the molecular basis of aging, it is critical to recognize the role of cellular homeostasis and repair systems. Autophagy, ubiquitin-proteasome degradation, DNA repair pathways like nucleotide excision repair and homologous recombination, and antioxidant defenses collectively form a network of maintenance activities that preserve cellular integrity. As organisms age, the efficiency of these systems declines, leading to the gradual accumulation of molecular errors. This decline can be influenced by environmental factors, genetic background, and stochastic events, highlighting the complex interplay that governs aging dynamics at the cellular level.

From an evolutionary standpoint, the weakening of selective pressures post-reproduction means deleterious mutations and suboptimal maintenance can accumulate without immediate consequence to fitness. The pleiotropic effects of genes beneficial early in life but harmful later on (antagonistic pleiotropy) and the accumulation of late-acting deleterious mutations provide further theoretical frameworks accounting for aging without invoking a programmed mechanism. This evolutionary backdrop supports the stochastic error accumulation model, framing aging as an emergent property of imperfect biology rather than a predetermined genetic program.

The implications of viewing aging through the lens of stochastic damage rather than a program extend profoundly into therapeutic strategies for healthy aging. Geroprotective interventions might find more success by targeting the enhancement of repair and maintenance pathways, rather than attempting to “turn off” an elusive aging program. Approaches such as boosting DNA repair enzymes, improving mitochondrial quality control, promoting proteostasis, and reducing oxidative stress are emerging as promising avenues to delay the functional decline associated with aging.

Furthermore, the application of aging clocks in clinical and research settings opens new opportunities for personalizing anti-aging therapies. By precisely measuring biological age and its deviation from chronological age, clinicians can monitor the effectiveness of interventions designed to bolster cellular maintenance. The ability to track dynamic changes in biological age could facilitate tailored treatments, optimizing healthspan extension on an individual level.

Importantly, the notion of system-wide entropy in biological aging underscores that aging is not localized but affects multiple cellular and tissue systems simultaneously. This multifactorial decline converges to reduce organismal resilience, increasing susceptibility to age-related diseases such as cancer, neurodegeneration, and metabolic disorders. The systemic nature of aging suggests that successful long-term interventions will require a comprehensive approach addressing multiple aspects of cellular and molecular maintenance.

Technological advances in genomics, proteomics, and imaging have bolstered our capacity to dissect the aging process with unprecedented resolution. These innovations enable the identification of critical nodes within maintenance networks that fail during aging. For example, recent data implicate specific DNA repair enzymes and stress response factors in preserving longevity, providing concrete molecular targets for intervention. Continued integration of multi-omics data will deepen mechanistic understanding and reveal synergistic pathways that could be harnessed therapeutically.

The cross-species comparative analysis of aging mechanisms adds another dimension to our understanding of longevity determinants. Studying long-lived species that naturally maintain high DNA repair fidelity and low damage accumulation offers models for therapeutic mimicry in humans. Such comparative biology approaches can identify conserved pathways that promote lifespan extension, guiding drug development and lifestyle modifications aimed at sustaining cellular health.

Despite the substantial progress, much remains to be elucidated about the heterogeneity of aging processes across tissues and individuals. Understanding why certain cell types or organs succumb earlier to damage accumulation could refine intervention timing and specificity. Additionally, decoding how stochastic molecular errors translate into macroscopic phenotypes like frailty will be critical for developing comprehensive aging models.

In summary, while aging clocks offer valuable insights by quantifying biological age, their existence does not confirm the presence of an inherent aging program. Rather, they measure the cumulative burden of molecular damage accrued via imperfect maintenance mechanisms, shaped over evolutionary time by relaxed selective pressures. Recognizing aging as a stochastic, error-driven process shifts the paradigm towards enhancing resilience and repair capacity to promote healthy lifespan extension in humans.

The convergence of molecular biology, evolutionary theory, and aging clock technology heralds a new era in aging research. By embracing the complexity and stochastic nature of aging, researchers and clinicians can devise more effective strategies for geroprotection grounded in mechanistic understanding. Ultimately, dismantling the myth of programmed aging in favor of a damage accumulation framework empowers the development of interventions that may one day transform human healthspan and vitality.

Subject of Research: Aging mechanisms and the debate over programmed versus stochastic causes of aging; evaluation of aging clocks as biomarkers of biological age.

Article Title: Aging by the clock and yet without a program.

Article References:
Meyer, D.H., Maklakov, A.A. & Schumacher, B. Aging by the clock and yet without a program. Nat Aging (2025). https://doi.org/10.1038/s43587-025-00975-2

Image Credits: AI Generated